Identification

Name
Ergoloid mesylate
Accession Number
DB01049  (APRD00711, DB01287)
Type
Small Molecule
Groups
Approved
Description

Ergoloid mesylate is a dihydrogenated ergot (Claviceps purpurea) derivative alkaloid used as a vasodilator agent. Ergoloid Mesylate is the only vasodilator that has shown mild benefits in the treatment of vascular dementia. Ergoloid Mesylate is a mixture of three different ergotamantriones: dihydroergocornine, dihydroergocristine, and dihydroergocryptine. It has been proposed to be a neuroprotective agent. The mechanism of its therapeutic actions is not clear.

Structure
Thumb
Synonyms
  • co-dergocrine mesilate
  • co-dergocrine mesylate
  • co-dergocrine methanesulfonate
  • codergocrine mesilate
  • codergocrine mesylate
  • codergocrine methanesulfonate
  • Dihydroergotoxine Mesilate
  • Dihydroergotoxine Mesylate
  • dihydroergotoxine methanesulfonate
  • Dihydroergotoxine Methanesulfonate
  • dihydroergotoxine methanesulfonates
  • dihydroergotoxine monomethanesulfonate
  • dihydrogenated ergot alkaloids
  • Ergoloid Mesylates
  • ergoloid methanesulfonate
  • ergoloid methanesulfonates
  • hydrogenated ergot alkaloids
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hydergine Tablets, 1mgTablet1 mgOralSterimax Inc1968-12-31Not applicableCanada
International/Other Brands
Alkergot / Circanol / Deapril / Gerimal / Hydergine / Hydergine LC
Categories
UNII
X3S33EX3KW
CAS number
8067-24-1
Weight
Average: 631.74
Monoisotopic: 631.267584003
Chemical Formula
C30H41N5O8S
InChI Key
FQHMMOGHDWAXDI-WUQHHHCFSA-N
InChI
InChI=1S/C29H37N5O5.CH4O3S/c1-15(2)28(27(37)34-16(3)26(36)33-10-6-9-23(33)29(34,38)39-28)31-25(35)18-11-20-19-7-5-8-21-24(19)17(13-30-21)12-22(20)32(4)14-18;1-5(2,3)4/h5,7-8,13,15-16,18,20,22-23,30,38H,6,9-12,14H2,1-4H3,(H,31,35);1H3,(H,2,3,4)/t16-,18+,20+,22+,23-,28+,29-;/m0./s1
IUPAC Name
(2R,4R,7R)-N-[(1S,2S,4R,7S)-2-hydroxy-7-methyl-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),9,12,14-tetraene-4-carboxamide; methanesulfonic acid
SMILES
CS(O)(=O)=O.[H][[email protected]@]12CCCN1C(=O)[[email protected]](C)N1C(=O)[[email protected]](NC(=O)[[email protected]]3CN(C)[[email protected]]4([H])CC5=CNC6=CC=CC(=C56)[[email protected]@]4([H])C3)(O[[email protected]@]21O)C(C)C

Pharmacology

Indication

For use as an adjunct therapy for patients with dementia.

Structured Indications
Pharmacodynamics

Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.

Mechanism of action

Ergoloid mesylates act centrally, decreasing vascular tone and slowing the heart rate, and acts peripherally to block alpha-receptors. One other possible mechanism is the effect of ergoloid mesylates on neuronal cell metabolism, resulting in improved oxygen uptake and cerebral metabolism, thereby normalizing depressed neurotransmitter levels.

TargetActionsOrganism
AAlpha-2 adrenergic receptors
antagonist
Human
AAlpha-1 adrenergic receptors
antagonist
Human
ASolute carrier organic anion transporter family member 2B1
inhibitor
Human
USerotonin Receptors
antagonist
Human
UD(1A) dopamine receptor
antagonist
agonist
Human
UD(2) dopamine receptor
antagonist
agonist
Human
UGABA-A receptor (anion channel)
agonist
Human
Absorption

Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.

Volume of distribution
Not Available
Protein binding

98-99%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

3.5 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Ergoloid mesylate can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Ergoloid mesylate can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Ergoloid mesylate can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
AcebutololAcebutolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Acetophenazine.Approved
AdrafinilErgoloid mesylate may increase the hypertensive activities of Adrafinil.Withdrawn
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Ergoloid mesylate.Approved, Investigational
AlogliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Ergoloid mesylate can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprenololAlprenolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Withdrawn
AmibegronErgoloid mesylate may increase the hypertensive activities of Amibegron.Investigational
AmiodaroneThe metabolism of Ergoloid mesylate can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Amisulpride.Approved, Investigational
AmitrazErgoloid mesylate may increase the hypertensive activities of Amitraz.Vet Approved
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ergoloid mesylate.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ergoloid mesylate.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Amperozide.Experimental
AmprenavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Amprenavir.Approved
AnisodamineErgoloid mesylate may increase the hypertensive activities of Anisodamine.Investigational
Antithrombin III humanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Apixaban.Approved
ApomorphineErgoloid mesylate may increase the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineErgoloid mesylate may increase the hypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Ergoloid mesylate can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Ergoloid mesylate can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineErgoloid mesylate may increase the hypertensive activities of Arbutamine.Approved
ArformoterolErgoloid mesylate may increase the hypertensive activities of Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
AsenapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Asenapine.Approved
AsunaprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Ergoloid mesylate can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
AtomoxetineThe metabolism of Ergoloid mesylate can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Azaperone.Vet Approved
BatimastatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Batimastat.Experimental
BefunololBefunolol may increase the vasoconstricting activities of Ergoloid mesylate.Experimental
BenazeprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Benazepril.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Ergoloid mesylate can be increased when it is combined with Benzamidine.Experimental
BetaxololBetaxolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
BevantololBevantolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Bifeprunox.Investigational
BisoprololBisoprolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
BitolterolErgoloid mesylate may increase the hypertensive activities of Bitolterol.Withdrawn
BivalirudinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Boceprevir.Withdrawn
BopindololBopindolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
BortezomibThe metabolism of Ergoloid mesylate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Brexpiprazole.Approved
BrimonidineErgoloid mesylate may increase the hypertensive activities of Brimonidine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Bromperidol.Investigational
BucindololBucindolol may increase the vasoconstricting activities of Ergoloid mesylate.Investigational
BufuralolBufuralol may increase the vasoconstricting activities of Ergoloid mesylate.Experimental, Investigational
BupranololBupranolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergoloid mesylate.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Butaperazine.Experimental
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ergoloid mesylate.Approved
CamostatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Ergoloid mesylate can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Carbomycin.Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Cariprazine.Approved
CarteololCarteolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
CarvedilolCarvedilol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
CeliprololCeliprolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
CeritinibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ergoloid mesylate.Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Ergoloid mesylate can be increased when it is combined with Cholesterol.Experimental
ChymostatinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Cilazapril.Approved
CirazolineErgoloid mesylate may increase the hypertensive activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Ergoloid mesylate.Approved
ClarithromycinThe metabolism of Ergoloid mesylate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ergoloid mesylate can be decreased when combined with Clemastine.Approved
ClenbuterolErgoloid mesylate may increase the hypertensive activities of Clenbuterol.Approved, Vet Approved
ClomipramineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clomipramine.Approved, Vet Approved
ClonidineErgoloid mesylate may increase the hypertensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clopenthixol.Experimental
CloranololCloranolol may increase the vasoconstricting activities of Ergoloid mesylate.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Clozapine.Approved
CobicistatThe metabolism of Ergoloid mesylate can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Ergoloid mesylate can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Cyamemazine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergoloid mesylate.Approved
CyclosporineThe metabolism of Ergoloid mesylate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Dabrafenib.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Ergoloid mesylate.Investigational
DarexabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Darexaban.Investigational
DarunavirThe metabolism of Ergoloid mesylate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Ergoloid mesylate can be decreased when combined with Delavirdine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Desipramine.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Desvenlafaxine.Approved
DetomidineErgoloid mesylate may increase the hypertensive activities of Detomidine.Vet Approved
DexmedetomidineErgoloid mesylate may increase the hypertensive activities of Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ergoloid mesylate.Approved
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ergoloid mesylate.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ergoloid mesylate.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Ergoloid mesylate.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ergoloid mesylate.Approved
DiltiazemThe metabolism of Ergoloid mesylate can be decreased when combined with Diltiazem.Approved
DipivefrinErgoloid mesylate may increase the hypertensive activities of Dipivefrin.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Dixyrazine.Experimental
DobutamineErgoloid mesylate may increase the hypertensive activities of Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Ergoloid mesylate.Approved
DopexamineErgoloid mesylate may increase the hypertensive activities of Dopexamine.Investigational
DoxepinThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Doxepin.Approved
DoxycyclineThe metabolism of Ergoloid mesylate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Ergoloid mesylate can be decreased when combined with Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Droperidol.Approved, Vet Approved
DroxidopaErgoloid mesylate may increase the hypertensive activities of Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ergoloid mesylate.Approved
EcabetThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ecabet.Approved, Investigational
EcopipamThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Edoxaban.Approved
ElafinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Elafin.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ergoloid mesylate.Approved, Investigational
EnalaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalkiren.Experimental
EnzalutamideThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the vasoconstricting activities of Ergoloid mesylate.Experimental
EphedrineErgoloid mesylate may increase the hypertensive activities of Ephedrine.Approved
Epigallocatechin GallateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinephrineErgoloid mesylate may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Ergoloid mesylate.Approved
ErythromycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Escitalopram.Approved, Investigational
EsmololEsmolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
EtilefrineErgoloid mesylate may increase the hypertensive activities of Etilefrine.Withdrawn
FaldaprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Faldaprevir.Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoterolErgoloid mesylate may increase the hypertensive activities of Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ergoloid mesylate.Approved, Illicit, Investigational, Vet Approved
FluanisoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Fluconazole.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergoloid mesylate.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluspirilene.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Ergoloid mesylate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ergoloid mesylate.Approved, Investigational
FormoterolErgoloid mesylate may increase the hypertensive activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Ergoloid mesylate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Ergoloid mesylate can be increased when combined with Fosphenytoin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Ergoloid mesylate.Approved, Investigational
Fusidic AcidThe serum concentration of Ergoloid mesylate can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Gabexate.Investigational
GeldanamycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Geldanamycin.Experimental
GM6001The serum concentration of Ergoloid mesylate can be increased when it is combined with GM6001.Experimental
GranisetronGranisetron may increase the serotonergic activities of Ergoloid mesylate.Approved, Investigational
GuanabenzErgoloid mesylate may increase the hypertensive activities of Guanabenz.Approved
GuanfacineErgoloid mesylate may increase the hypertensive activities of Guanfacine.Approved, Investigational
HaloperidolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Haloperidol.Approved
HexoprenalineErgoloid mesylate may increase the hypertensive activities of Hexoprenaline.Approved, Withdrawn
HigenamineErgoloid mesylate may increase the hypertensive activities of Higenamine.Investigational
IdelalisibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Ergoloid mesylate can be increased when it is combined with Idraparinux.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Iloperidone.Approved
ImatinibThe metabolism of Ergoloid mesylate can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ergoloid mesylate.Approved
IndenololIndenolol may increase the vasoconstricting activities of Ergoloid mesylate.Withdrawn
IndinavirThe metabolism of Ergoloid mesylate can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Ergoloid mesylate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Isocarboxazid.Approved
IsoetarineErgoloid mesylate may increase the hypertensive activities of Isoetarine.Approved
IsoflurophateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Isoflurophate.Approved, Withdrawn
IsoprenalineErgoloid mesylate may increase the hypertensive activities of Isoprenaline.Approved
IsoxsuprineErgoloid mesylate may increase the hypertensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Ergoloid mesylate can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Josamycin.Approved
KetoconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
LandiololLandiolol may increase the vasoconstricting activities of Ergoloid mesylate.Investigational
LepirudinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Letaxaban.Investigational
LevobunololLevobunolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Levomilnacipran.Approved
LinagliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Linagliptin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Ergoloid mesylate.Approved, Investigational
LisinoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideErgoloid mesylate may increase the vasoconstricting activities of Lisuride.Approved
LithiumThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lithium.Approved
LofexidineErgoloid mesylate may increase the hypertensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Ergoloid mesylate can be decreased when combined with Lopinavir.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ergoloid mesylate.Approved
LovastatinThe metabolism of Ergoloid mesylate can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ergoloid mesylate can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lurasidone.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Ergoloid mesylate.Illicit, Withdrawn
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ergoloid mesylate.Approved
MedetomidineErgoloid mesylate may increase the hypertensive activities of Medetomidine.Vet Approved
MelagatranThe serum concentration of Ergoloid mesylate can be increased when it is combined with Melagatran.Experimental
MelperoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Melperone.Approved
MephentermineErgoloid mesylate may increase the hypertensive activities of Mephentermine.Approved
MepindololMepindolol may increase the vasoconstricting activities of Ergoloid mesylate.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Mesoridazine.Approved
MetaraminolErgoloid mesylate may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Ergoloid mesylate.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ergoloid mesylate.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Methotrimeprazine.Approved
MethoxamineErgoloid mesylate may increase the hypertensive activities of Methoxamine.Approved
MethoxyphenamineErgoloid mesylate may increase the hypertensive activities of Methoxyphenamine.Experimental
MethyldopaErgoloid mesylate may increase the hypertensive activities of Methyldopa.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Ergoloid mesylate.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Ergoloid mesylate.Approved
MetipranololMetipranolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Metoclopramide.Approved, Investigational
MetoprololMetoprolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Ergoloid mesylate.Experimental
MidodrineErgoloid mesylate may increase the hypertensive activities of Midodrine.Approved
MifepristoneThe serum concentration of Ergoloid mesylate can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Milnacipran.Approved
MirabegronErgoloid mesylate may increase the hypertensive activities of Mirabegron.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ergoloid mesylate.Approved
MitotaneThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Mitotane.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Moclobemide.Approved
MoexiprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Moperone.Experimental
MosapramineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Mosapramine.Experimental
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Ergoloid mesylate can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NadololNadolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
NafamostatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Nafamostat.Approved, Investigational
NaphazolineErgoloid mesylate may increase the hypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Ergoloid mesylate.Approved, Investigational
NebivololErgoloid mesylate may increase the hypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Ergoloid mesylate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ergoloid mesylate can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ergoloid mesylate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ergoloid mesylate can be increased when combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Ergoloid mesylate.Approved
NilotinibThe metabolism of Ergoloid mesylate can be decreased when combined with Nilotinib.Approved, Investigational
NitroaspirinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Nitroaspirin.Investigational
NitroglycerinErgoloid mesylate may decrease the vasodilatory activities of Nitroglycerin.Approved, Investigational
NorepinephrineErgoloid mesylate may increase the hypertensive activities of Norepinephrine.Approved
NorfenefrineErgoloid mesylate may increase the hypertensive activities of Norfenefrine.Experimental
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ergoloid mesylate.Approved
NylidrinErgoloid mesylate may increase the hypertensive activities of Nylidrin.Approved
OctopamineErgoloid mesylate may increase the hypertensive activities of Octopamine.Experimental
OlanzapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Ergoloid mesylate can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Oleandomycin.Vet Approved
OlodaterolErgoloid mesylate may increase the hypertensive activities of Olodaterol.Approved
OmapatrilatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Omapatrilat.Investigational
OndansetronOndansetron may increase the serotonergic activities of Ergoloid mesylate.Approved
OrciprenalineErgoloid mesylate may increase the hypertensive activities of Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Otamixaban.Investigational
OxprenololOxprenolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
OxyfedrineErgoloid mesylate may increase the hypertensive activities of Oxyfedrine.Experimental
OxymetazolineErgoloid mesylate may increase the hypertensive activities of Oxymetazoline.Approved
OxypertineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Oxypertine.Experimental
PalbociclibThe serum concentration of Ergoloid mesylate can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Ergoloid mesylate.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ergoloid mesylate.Approved, Investigational
PenbutololPenbutolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Penfluridol.Experimental
PentobarbitalThe metabolism of Ergoloid mesylate can be increased when combined with Pentobarbital.Approved, Vet Approved
PerazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perazine.Investigational
PergolideErgoloid mesylate may increase the vasoconstricting activities of Pergolide.Approved, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ergoloid mesylate.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ergoloid mesylate.Approved
PhenobarbitalThe metabolism of Ergoloid mesylate can be increased when combined with Phenobarbital.Approved
PhenylephrineErgoloid mesylate may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineErgoloid mesylate may increase the hypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Ergoloid mesylate can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Ergoloid mesylate can be increased when it is combined with Phosphoramidon.Experimental
PiclozotanErgoloid mesylate may increase the vasoconstricting activities of Piclozotan.Investigational
PimozideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pimozide.Approved
PindololPindolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pipotiazine.Approved
PirbuterolErgoloid mesylate may increase the hypertensive activities of Pirbuterol.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ergoloid mesylate.Approved
PosaconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Ergoloid mesylate.Approved
PrenalterolErgoloid mesylate may increase the hypertensive activities of Prenalterol.Experimental
PrimidoneThe metabolism of Ergoloid mesylate can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Prinomastat.Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Procarbazine.Approved
ProcaterolErgoloid mesylate may increase the hypertensive activities of Procaterol.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Promethazine.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Propericiazine.Approved
PropranololPropranolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ergoloid mesylate.Approved
PRX-00023Ergoloid mesylate may increase the vasoconstricting activities of PRX-00023.Investigational
PseudoephedrineErgoloid mesylate may increase the hypertensive activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Quetiapine.Approved
QuinaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Quinapril.Approved, Investigational
RacecadotrilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Racecadotril.Investigational
RacepinephrineErgoloid mesylate may increase the hypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Raclopride.Investigational
RactopamineErgoloid mesylate may increase the hypertensive activities of Ractopamine.Vet Approved
RamiprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ramipril.Approved
RanolazineThe metabolism of Ergoloid mesylate can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Rasagiline.Approved
RemikirenThe serum concentration of Ergoloid mesylate can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Remoxipride.Approved, Withdrawn
ReproterolErgoloid mesylate may increase the hypertensive activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Reserpine.Approved
RifabutinThe metabolism of Ergoloid mesylate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ergoloid mesylate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ergoloid mesylate can be increased when combined with Rifapentine.Approved
RilmenidineErgoloid mesylate may increase the hypertensive activities of Rilmenidine.Investigational
RimiterolErgoloid mesylate may increase the hypertensive activities of Rimiterol.Experimental
RisperidoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ritanserin.Investigational
RitobegronErgoloid mesylate may increase the hypertensive activities of Ritobegron.Investigational
RitodrineErgoloid mesylate may increase the hypertensive activities of Ritodrine.Approved
RitonavirThe metabolism of Ergoloid mesylate can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Ergoloid mesylate.Approved
RomifidineErgoloid mesylate may increase the hypertensive activities of Romifidine.Vet Approved
RopiniroleErgoloid mesylate may increase the vasoconstricting activities of Ropinirole.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ergoloid mesylate.Approved
RoxithromycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Roxithromycin.Approved, Withdrawn
S-3304The serum concentration of Ergoloid mesylate can be increased when it is combined with S-3304.Investigational
SalbutamolErgoloid mesylate may increase the hypertensive activities of Salbutamol.Approved, Vet Approved
SalmeterolErgoloid mesylate may increase the hypertensive activities of Salmeterol.Approved
SaquinavirThe metabolism of Ergoloid mesylate can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Saxagliptin.Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Ergoloid mesylate.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sertraline.Approved
SildenafilThe metabolism of Ergoloid mesylate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ergoloid mesylate.Approved
SitagliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Ergoloid mesylate can be increased when it is combined with Sivelestat.Investigational
SolabegronErgoloid mesylate may increase the hypertensive activities of Solabegron.Investigational
SolithromycinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Solithromycin.Investigational
SotalolSotalol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
SpiraprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Spirapril.Approved
St. John's WortThe serum concentration of Ergoloid mesylate can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Ergoloid mesylate can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Ergoloid mesylate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Ergoloid mesylate.Approved, Investigational
SynephrineErgoloid mesylate may increase the hypertensive activities of Synephrine.Experimental
TalinololTalinolol may increase the vasoconstricting activities of Ergoloid mesylate.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Ergoloid mesylate.Approved
TelaprevirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Ergoloid mesylate can be decreased when combined with Telithromycin.Approved
TemocaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Temocapril.Experimental, Investigational
TerbutalineErgoloid mesylate may increase the hypertensive activities of Terbutaline.Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Ergoloid mesylate.Experimental
TertatololTertatolol may increase the vasoconstricting activities of Ergoloid mesylate.Experimental
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tetrahydropalmatine.Investigational
ThiopropazateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thioridazine.Withdrawn
ThiorphanThe serum concentration of Ergoloid mesylate can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thiothixene.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Ergoloid mesylate can be decreased when combined with Ticlopidine.Approved
TimololTimolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
TipranavirThe serum concentration of Ergoloid mesylate can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineErgoloid mesylate may increase the hypertensive activities of Tizanidine.Approved
TocilizumabThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Tocilizumab.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergoloid mesylate.Approved, Investigational
TrandolaprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ergoloid mesylate.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergoloid mesylate.Approved, Investigational
TretoquinolErgoloid mesylate may increase the hypertensive activities of Tretoquinol.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ergoloid mesylate.Approved
TropisetronTropisetron may increase the serotonergic activities of Ergoloid mesylate.Approved, Investigational
TulobuterolErgoloid mesylate may increase the hypertensive activities of Tulobuterol.Investigational
TylosinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ubenimex.Experimental
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Ergoloid mesylate.Experimental
UlinastatinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ulinastatin.Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Ergoloid mesylate.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Veralipride.Experimental
VerapamilThe metabolism of Ergoloid mesylate can be decreased when combined with Verapamil.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Vilazodone.Approved
VildagliptinThe serum concentration of Ergoloid mesylate can be increased when it is combined with Vildagliptin.Approved, Investigational
VoriconazoleThe serum concentration of Ergoloid mesylate can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Vortioxetine.Approved
XamoterolErgoloid mesylate may increase the hypertensive activities of Xamoterol.Experimental
XimelagatranThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineErgoloid mesylate may increase the hypertensive activities of Xylazine.Vet Approved
YM-178Ergoloid mesylate may increase the hypertensive activities of YM-178.Investigational
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Ergoloid mesylate can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZiprasidoneThe metabolism of Ergoloid mesylate can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe serum concentration of Ergoloid mesylate can be increased when it is combined with Zofenopril.Experimental
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ergoloid mesylate.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D02268
KEGG Compound
C14055
ChEBI
34706
Therapeutic Targets Database
DAP000901
PharmGKB
PA164752439
Wikipedia
Ergoloid
ATC Codes
C04AE51 — Ergoloid mesylates, combinationsC04AE01 — Ergoloid mesylates
AHFS Codes
  • 12:16.00 — Sympatholytic (Adrenergic Blocking) Agents
MSDS
Download (72.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentDementia, Vascular1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral1 mg
Prices
Unit descriptionCostUnit
Ergoloid mesylates powder87.5USD g
Ergoloid mesylates 1 mg tablet1.3USD tablet
Hydergine 1 mg Tablet1.1USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.8Not Available
Predicted Properties
PropertyValueSource
logP2.17ChemAxon
pKa (Strongest Acidic)9.71ChemAxon
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.21 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity143.66 m3·mol-1ChemAxon
Polarizability57.99 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8284
Blood Brain Barrier-0.9494
Caco-2 permeable-0.6447
P-glycoprotein substrateSubstrate0.6838
P-glycoprotein inhibitor IInhibitor0.6581
P-glycoprotein inhibitor IINon-inhibitor0.8001
Renal organic cation transporterNon-inhibitor0.8838
CYP450 2C9 substrateNon-substrate0.75
CYP450 2D6 substrateNon-substrate0.7966
CYP450 3A4 substrateSubstrate0.6681
CYP450 1A2 substrateNon-inhibitor0.7702
CYP450 2C9 inhibitorNon-inhibitor0.7072
CYP450 2D6 inhibitorNon-inhibitor0.9221
CYP450 2C19 inhibitorNon-inhibitor0.6493
CYP450 3A4 inhibitorNon-inhibitor0.7973
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8464
Ames testNon AMES toxic0.6324
CarcinogenicityNon-carcinogens0.6535
BiodegradationNot ready biodegradable0.9321
Rat acute toxicity2.5438 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8821
hERG inhibition (predictor II)Inhibitor0.5783
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as ergopeptines. These are ergoline derivatives that contain a tripeptide structure attached to the basic ergoline ring in the same location as the amide group of the lysergic acid derivatives.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Ergoline and derivatives
Sub Class
Lysergic acids and derivatives
Direct Parent
Ergopeptines
Alternative Parents
Hybrid peptides / Dipeptides / Lysergamides / Indoloquinolines / Benzoquinolines / Quinoline-3-carboxamides / Pyrroloquinolines / N-acyl-alpha amino acids and derivatives / 3-alkylindoles / Piperidinecarboxamides
show 20 more
Substituents
Ergopeptine / Hybrid peptide / Alpha-dipeptide / Lysergic acid amide / Indoloquinoline / Benzoquinoline / Quinoline-3-carboxamide / N-acyl-alpha amino acid or derivatives / Pyrroloquinoline / Alpha-amino acid or derivatives
show 41 more
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...

Components:
References
  1. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188]
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Lu WJ, Huang JD, Lai ML: The effects of ergoloid mesylates and ginkgo biloba on the pharmacokinetics of ticlopidine. J Clin Pharmacol. 2006 Jun;46(6):628-34. [PubMed:16707409]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...

Components:
References
  1. Flynn BL, Ranno AE: Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. [PubMed:10084415]
  2. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188]
  3. Wadworth AN, Chrisp P: Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline. Drugs Aging. 1992 May-Jun;2(3):153-73. [PubMed:1606351]
  4. Korneyev AY, Cincotta AH: Identification of hepatic, non-monoamine, dihydroergocryptine binding sites with significant gender differences. Life Sci. 1996;58(12):241-8. [PubMed:8786706]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Flynn BL, Ranno AE: Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. [PubMed:10084415]
  2. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188]
  3. Wadworth AN, Chrisp P: Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline. Drugs Aging. 1992 May-Jun;2(3):153-73. [PubMed:1606351]
  4. Korneyev AY, Cincotta AH: Identification of hepatic, non-monoamine, dihydroergocryptine binding sites with significant gender differences. Life Sci. 1996;58(12):241-8. [PubMed:8786706]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Agonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17. [PubMed:2869188]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...

Components:
References
  1. Tvrdeic A, Pericic D: Effect of ergot alkaloids on 3H-flunitrazepam binding to mouse brain GABAA receptors. Coll Antropol. 2003;27 Suppl 1:175-82. [PubMed:12955907]
  2. Tvrdeic A, Pericic D: Dihydrogenated ergot compounds bind with high affinity to GABAA receptor-associated Cl- ionophore. Eur J Pharmacol. 1991 Sep 4;202(1):109-11. [PubMed:1664802]
  3. Korneyev AY, Cincotta AH: Identification of hepatic, non-monoamine, dihydroergocryptine binding sites with significant gender differences. Life Sci. 1996;58(12):241-8. [PubMed:8786706]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Althaus M, Retzow A, Castell JV, Gomez-Lechon MJ, Amalou Z, Rose T, Appel K: In vitro identification of the cytochrome P450 isoform responsible for the metabolism of alpha-dihydroergocryptine. Xenobiotica. 2000 Nov;30(11):1033-45. [PubMed:11197065]

Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13